Get the Stockscreener App
1.97
11.30%
0.20
After Hours:
2.00
0.03
+1.52%
MAIA Biotechnology Inc stock is traded at $1.97, with a volume of 527.86K.
It is up +11.30% in the last 24 hours and up +25.48% over the past month.
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.
See More
Previous Close:
$1.77
Open:
$1.77
24h Volume:
527.86K
Relative Volume:
0.62
Market Cap:
$72.95M
Revenue:
-
Net Income/Loss:
$-25.94M
P/E Ratio:
-1.4275
EPS:
-1.38
Net Cash Flow:
$-15.79M
1W Performance:
+3.14%
1M Performance:
+25.48%
6M Performance:
+25.48%
1Y Performance:
+5.35%
1-Day Range:
$1.72
$1.97
1-Week Range:
$1.69
$2.0499
52-Week Range:
$0.87
$3.19
MAIA Biotechnology Inc Stock (MAIA) Company Profile
Name
MAIA Biotechnology Inc
Sector
Industry
Phone
312 416 8592
Address
444 West Lake Street, Suite 1700, Chicago
Compare MAIA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MAIA
MAIA Biotechnology Inc
|
1.97 | 65.55M | 0 | -25.94M | -15.79M | -1.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
MAIA Biotechnology Inc Stock (MAIA) Latest News
What are the future prospects of MAIA Biotechnology IncSwing Trade & Daily Technical Forecast Reports - baoquankhu1.vn
MAIA Biotechnology (NYSEAMERICAN:MAIA) Shares Up 0.5% – Should You Buy? - Defense World
MAIA Biotechnology (NYSEAMERICAN:MAIA) Shares Up 0.5%Should You Buy? - MarketBeat
Fed Watch: Will MAIA Biotechnology Inc outperform small cap indexes2025 Market Sentiment & Safe Investment Capital Preservation Plans - baoquankhu1.vn
MAIA Biotechnology announces significant insider buying - MSN
Risk Analysis: Is Roblox Corporation stock risky to hold now2025 Year in Review & High Accuracy Investment Signals - baoquankhu1.vn
$207B Market Shift: The Race for Fast Track Approval in Oncology (2026-02-05) - Seeking Alpha
$207B Market Shift: The Race for Fast Track Approval in Oncology - Sahm
Geopolitics Watch: What are the future prospects of MAIA Biotechnology IncTrade Analysis Summary & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment - The Globe and Mail
Late-Stage Breakthroughs: How 2026’s Top Clinical Platforms Are Redefining Cancer Treatment - Cantech Letter
Growth Value: Is MAIA Biotechnology Inc stock forming a cup and handleJuly 2025 Gainers & Long Hold Capital Preservation Plans - baoquankhu1.vn
Aug Highlights: What is MAIA Biotechnology Incs TAM Total Addressable Market2025 Institutional Moves & Stock Timing and Entry Methods - baoquankhu1.vn
Buyback Watch: Is Milestone Pharmaceuticals Inc undervalued by DCF analysis2025 Volume Leaders & Fast Momentum Stock Entry Tips - baoquankhu1.vn
Tech Rally: What are the future prospects of MAIA Biotechnology Inc2025 Growth vs Value & Accurate Buy Signal Notifications - baoquankhu1.vn
MAIA 's Outlines 2026 Milestones On Ateganosine In Cancer Treatment Program; Stock Down - Nasdaq
MAIA Biotechnology outlines 2026 goals for ateganosine program - TipRanks
MAIA Biotechnology Advances Ateganosine Cancer Treatment Program - TradingView — Track All Markets
MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum - The Manila Times
MAIA Biotechnology Advances Ateganosine Cancer Treatment - GlobeNewswire
MAIA Biotechnology (NYSEAMERICAN:MAIA) Shares Up 9.4% – Time to Buy? - Defense World
MAIA Biotechnology (NYSEAMERICAN:MAIA) Shares Up 9.4%Time to Buy? - MarketBeat
Trend Report: Should I buy BOSC stock nowJuly 2025 Highlights & AI Powered Trade Plan Recommendations - baoquankhu1.vn
MAIA Biotechnology (MAIA) Price Target Decreased by 15.37% to 10.48 - Nasdaq
MAIA Biotechnology Highlights Strategy in New Investor Presentation - TipRanks
Smith Stan buys MAIA Biotechnology shares worth $9,958 By Investing.com - Investing.com Australia
Smith Stan buys MAIA Biotechnology shares worth $9,958 - Investing.com
Will MAIA Biotechnology Inc. stock sustain dividend payoutsJuly 2025 Opening Moves & Risk Managed Investment Strategies - Улправда
Will MAIA Biotechnology Inc. stock deliver compounding returns2025 Fundamental Recap & AI Forecasted Entry and Exit Points - Улправда
Can MAIA Biotechnology Inc. stock deliver strong annual returnsWeekly Trade Recap & Expert Curated Trade Ideas - Улправда
MAIA Biotechnology (MAIA) director granted 24,060 options under 2021 plan - Stock Titan
MAIA Biotechnology (MAIA) director reports grant of 29,216 stock options - Stock Titan
MAIA Biotechnology (MAIA) director receives 25,206 stock options exercisable at $1.53 - Stock Titan
MAIA Biotechnology, Inc. (MAIA) reports 29,789 director stock options at $1.53 - Stock Titan
[Form 4] MAIA Biotechnology, Inc. Insider Trading Activity - Stock Titan
MAIA Biotechnology (NASDAQ: MAIA) reports 24,633 stock options grant - Stock Titan
A stock that deserves closer examination: MAIA Biotechnology Inc (MAIA) - uspostnews.com
MAIA Biotechnology, Inc. Common Stock (NYSE:MAIA) Stock Quote - FinancialContent
MAIA Biotechnology announces open market purchases by CEO, directors - MSN
MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Short Interest Up 144.9% in December - MarketBeat
MAIA Biotechnology (MAIA) Price Target Decreased by 13.32% to 12.38 - MSN
MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings - The Manila Times
Louie Ngar Yee buys MAIA Biotechnology (MAIA) shares worth $99999 By Investing.com - Investing.com Canada
Stan Smith buys MAIA Biotechnology shares worth $69,999 By Investing.com - Investing.com Canada
Chaouki Steven M buys MAIA Biotechnology shares worth $49999 By Investing.com - Investing.com Australia
Stan Smith buys MAIA Biotechnology shares worth $69,999 - Investing.com
Louie Ngar Yee buys MAIA Biotechnology (MAIA) shares worth $99999 - Investing.com
MAIA Biotechnology Directors Increase Holdings - TradingView — Track All Markets
MAIA (MAIA) director boosts stake with 57,189-share buy and new options - Stock Titan
MAIA Biotechnology (MAIA) director reports stock purchase and new options - Stock Titan
MAIA Biotechnology Inc Stock (MAIA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Cap:
|
Volume (24h):